NMRK2 and sarcopenia: As muscle NRK2 loss occurred independently of CC status, i.e., body weight loss and/or sarcopenia, this emphasizes that NAD+ metabolism could be a feasible target for early interventions to improve cancer patient health before overt or refractory CC ensue.